Atara Biotherapeutics Stock Today

ATRA Stock  USD 0.77  0.01  1.28%   


6 of 100


Odds Of Distress

Over 75

Atara Biotherapeutics is trading at 0.77 as of the 4th of March 2024, a -1.28 percent down since the beginning of the trading day. The stock's open price was 0.78. Atara Biotherapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Atara Biotherapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of February 2024 and ending today, the 4th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
16th of October 2014
Health Care
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company was incorporated in 2012 and is headquartered in South San Francisco, California. The company has 101.92 M outstanding shares of which 10.87 M shares are presently shorted by private and institutional investors with about 2.47 trading days to cover. More on Atara Biotherapeutics

Moving against Atara Stock

  0.55VCYT Veracyte Financial Report 2nd of May 2024 PairCorr
  0.54YS YS Biopharma Report 22nd of April 2024 PairCorr
  0.54DMTK DermTech Report 7th of March 2024 PairCorr
  0.52VALN Valneva SE ADR Report 28th of March 2024 PairCorr
  0.51DNLI Denali Therapeutics Financial Report 13th of May 2024 PairCorr
  0.5ME 23Andme HoldingPairCorr
  0.47DRMA Dermata Therapeutics Financial Report 9th of May 2024 PairCorr

Atara Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Atara Biotherapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Atara Biotherapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
President CEO, DirectorPascal Touchon
Thematic IdeaCancer Fighters (View all Themes)
SEC FilingsAtara Biotherapeutics Security & Exchange Commission EDGAR Reports
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Atara Biotherapeutics report their recommendations after researching Atara Biotherapeutics' financial statements, talking to executives and customers, or listening in on Atara Biotherapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Atara Biotherapeutics. The Atara consensus assessment is calculated by taking the average forecast from all of the analysts covering Atara Biotherapeutics.
Financial Strength
Based on the key indicators related to Atara Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, Atara Biotherapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. Financial strength of Atara Biotherapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Shares Diluted126.5 M117.3 M
Significantly Up
Slightly volatile
Weighted Shares126.5 M117.3 M
Significantly Up
Slightly volatile
Current Liabilities97.9 M90.8 M
Significantly Up
Slightly volatile
Total Liabilities309.9 M287.2 M
Significantly Up
Slightly volatile
Gross Margin0.890.9
Fairly Down
Slightly volatile
Total Debt109.6 M101.5 M
Significantly Up
Slightly volatile
Asset Turnover0.160.19
Fairly Down
Slightly volatile
Current Assets335.6 M339.3 M
Fairly Down
Slightly volatile
Total Assets409.2 M432.9 M
Notably Down
Slightly volatile
Atara Biotherapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Atara Biotherapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Atara Biotherapeutics' financial leverage. It provides some insight into what part of Atara Biotherapeutics' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Atara Biotherapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Atara Biotherapeutics deploys its capital and how much of that capital is borrowed.
Atara Biotherapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 71.7 M in liabilities with Debt to Equity (D/E) ratio of 0.29, which may suggest the company is not taking enough advantage from borrowing. Atara Biotherapeutics has a current ratio of 5.17, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Atara Biotherapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Atara Biotherapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Atara Biotherapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Atara to invest in growth at high rates of return. When we think about Atara Biotherapeutics' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(249.79 Million)
Atara Biotherapeutics (ATRA) is traded on NASDAQ Exchange in USA. It is located in 2380 Conejo Spectrum Street, Thousand Oaks, CA, United States, 91320 and employs 334 people. Atara Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 78.55 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Atara Biotherapeutics's market, we take the total number of its shares issued and multiply it by Atara Biotherapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Atara Biotherapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 101.92 M outstanding shares of which 10.87 M shares are presently shorted by private and institutional investors with about 2.47 trading days to cover. Atara Biotherapeutics currently holds about 331.31 M in cash with (199.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.51, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Atara Biotherapeutics Probability Of Bankruptcy
Ownership Allocation
Atara Biotherapeutics holds a total of one hundred one million nine hundred twenty-two thousand outstanding shares. Over half of Atara Biotherapeutics outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Atara Biotherapeutics. Please watch out for any change in the institutional holdings of Atara Biotherapeutics as this could mean something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Atara Ownership Details

Atara Stock Price Odds Analysis

What are Atara Biotherapeutics' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Atara Biotherapeutics jumping above the current price in 90 days from now is about 27.43%. The Atara Biotherapeutics probability density function shows the probability of Atara Biotherapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.3101. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Atara Biotherapeutics will likely underperform. Additionally, the company has an alpha of 0.4221, implying that it can generate a 0.42 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 0.77HorizonTargetOdds Above 0.77
72.49%90 days
Based on a normal probability distribution, the odds of Atara Biotherapeutics to move above the current price in 90 days from now is about 27.43 (This Atara Biotherapeutics probability density function shows the probability of Atara Stock to fall within a particular range of prices over 90 days) .

Atara Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Atara Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Atara Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Atara Biotherapeutics' value.
InstituionRecorded OnShares
Ameriprise Financial Inc2023-09-30
1.7 M
Antipodean Advisors Llc2023-09-30
1000 K
Staley Capital Advisers Inc2023-12-31
1000 K
Northern Trust Corp2023-09-30
798.9 K
Charles Schwab Investment Management Inc2023-09-30
793.6 K
Gsa Capital Partners Llp2023-12-31
784.4 K
Renaissance Technologies Corp2023-12-31
622.9 K
Jacobs Levy Equity Management, Inc.2023-09-30
566.9 K
Point72 Asset Management, L.p.2023-09-30
555 K
Jpmorgan Chase & Co2023-09-30
8.7 M
Blackrock Inc2023-12-31
7.1 M
View Atara Biotherapeutics Diagnostics

Atara Biotherapeutics Historical Income Statement

Atara Biotherapeutics Income Statement is one of the three primary financial statements used for reporting Atara's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Atara Biotherapeutics revenue and expense. Atara Biotherapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Atara Biotherapeutics' Research and Development Expense is projected to increase significantly based on the last few years of reporting. The current year's Weighted Average Shares is expected to grow to about 126.5 M, whereas Consolidated Income is forecasted to decline to (221.7 M). View More Fundamentals

Atara Stock Against Markets

Picking the right benchmark for Atara Biotherapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Atara Biotherapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Atara Biotherapeutics is critical whether you are bullish or bearish towards Atara Biotherapeutics at a given time. Please also check how Atara Biotherapeutics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Atara Biotherapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Comparator Now


Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module

Atara Biotherapeutics Corporate Directors

Atara Biotherapeutics corporate directors refer to members of an Atara Biotherapeutics board of directors. The board of directors generally takes responsibility for the Atara Biotherapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Atara Biotherapeutics' board members must vote for the resolution. The Atara Biotherapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Roy BaynesIndependent DirectorProfile
Carol GallagherLead Independent DirectorProfile
Eric DobmeierDirectorProfile
William HeidenIndependent DirectorProfile

How to buy Atara Stock?

Before investing in Atara Biotherapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Atara Biotherapeutics. To buy Atara Biotherapeutics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Atara Biotherapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Atara Biotherapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Atara Biotherapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Atara Biotherapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Atara Biotherapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Atara Stock please use our How to Invest in Atara Biotherapeutics guide.

Already Invested in Atara Biotherapeutics?

The danger of trading Atara Biotherapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Atara Biotherapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Atara Biotherapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Atara Biotherapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Atara Stock analysis

When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Is Atara Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
Return On Equity
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.